Highlights
- Recruitment for the AIPAC study expected to be completed in Q2 2019
- 15 patients enrolled in TACTI-002 Phase II collaboration study with MSD
- Trial protocol approved for the INSIGHT-004 Phase 1 collaboration study with Merck KGaA and Pfizer.
- Ongoing progress with partnered programs
SYDNEY, AUSTRALIA – April 30, 2019 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update for the ongoing development of its product candidates.
For further information please download PDF attached:
Download this document
